Prescriber's Corner

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma

Lindsay Shelledy, PharmD, and Danielle Roman, PharmD, BCOP

West Penn Allegheny Oncology Network, Pittsburgh, Pennsylvania

Danielle Roman, PharmD, BCOP, West Penn Allegheny Oncology Network, Allegheny Health Network Cancer Institute, 4815 Liberty Avenue, Suite 340, Pittsburgh, PA 15317. E-mail: droman@wpaon.org


J Adv Pract Oncol 2015;6:361–365 | DOI: 10.6004/jadpro.2015.6.4.6 | © 2015 Harborside Press®


  



For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here